We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Company says it received conditional approval for bird flu vaccine from US Department of Agriculture
Zoetis, the manufacturer behind the vaccine, announced the conditional approval Friday, saying in a news release its scientists had begun updating its existing avian flu vaccine in 2022.
Companion animal product sales grew 8%, while livestock sales declined 3%. These results reflect Zoetis's strong operational capacity, despite facing challenges within the livestock segment.
In its fourth quarter 2024 investor letter, Polen Focus Growth Strategy emphasized stocks such as Zoetis Inc. (NYSE:ZTS). Zoetis Inc. (NYSE: ZTS) is involved in the research, development ...
Shares of Zoetis (NYSE: ZTS), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up short in its fourth quarter. Though it topped estimates on the top and ...
CEO Kristin Peck highlighted Zoetis delivered an excellent 2024, achieving double-digit operational revenue growth of 11% and adjusted net income growth of 15%. U.S. and international revenues ...
Parsippany, New Jersey-based Zoetis Inc. (ZTS) discovers, develops, and commercializes animal health medicines, vaccines, and diagnostic products and services. With a market cap of $74.8 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results